Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013804 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1 study of Advanced Malignancies, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 6
- Study locations
NCT02013804 is a Phase 1 study of Advanced Malignancies that has completed, run by MedImmune. The registered enrollment target is 58 participants, below the 83-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (30% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02013804, a Phase 1 study of Advanced Malignancies, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.
Conditions Studied
Interventions
- DRUG MEDI0680 (AMP-514)
Study Locations (6)
Connecticut
- Research Site - New Haven
Michigan
- Research Site - Detroit
New York
- Research Site - The Bronx
Oregon
- Research Site - Portland
Tennessee
- Research Site - Nashville
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2013-12-19 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013804
The ClinicalTrials.gov registry entry for NCT02013804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (30% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MEDI0680 (AMP-514) is the first listed.
NCT02013804 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Connecticut, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02013804 about?
NCT02013804 is a clinical study titled "A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies". This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.
What is the current status of trial NCT02013804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2013-12-19. Estimated completion is 2017-05-18.
What conditions does trial NCT02013804 study?
This clinical trial studies the following conditions: Advanced Malignancies.
What interventions are being tested in trial NCT02013804?
The interventions under investigation include: MEDI0680 (AMP-514) (DRUG).
Who is sponsoring clinical trial NCT02013804?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02013804 being conducted?
This trial has 6 study locations across Connecticut, Michigan, New York, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
COMPLETED · Phase 1
-
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
COMPLETED · Phase 1
-
Maintenance Study on the Long Term Safety of XL999
COMPLETED · Phase 1
-
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.